Cerebral ischaemic lesions and oral contraception.
D000293:Adolescent; D000328:Adult; D002561:Cerebrovascular Disorders / Q000139:chemically induced*; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005040:Ethynodiol Diacetate / Q000009:adverse effects; D005260:Female; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000139:chemically induced; D002546:Ischemic Attack, Transient / Q000139:chemically induced; D008234:Lynestrenol / Q000009:adverse effects; D008535:Megestrol / Q000009:adverse effects; D008656:Mestranol / Q000009:adverse effects; D008875:Middle Aged; D009640:Norethindrone / Q000009:adverse effects; D009641:Norethynodrel / Q000009:adverse effects; D009644:Norgestrel / Q000009:adverse effects; D011247:Pregnancy
D003276:Contraceptives, Oral; D009644:Norgestrel; D004997:Ethinyl Estradiol; D005040:Ethynodiol Diacetate; D009641:Norethynodrel; D008656:Mestranol; D008535:Megestrol; D008234:Lynestrenol; D009640:Norethindrone